Overview
- 5 public-safe observations are available for this inspection.
- 5 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
9 Apr 2009
21 CFR 211.42(a)
Buildings of Suitable Size, Construction, Location
Cited by Susan M Jackson, Michele Perry Williams
9 Apr 2009
21 CFR 211.80(b)
Handling and Storage to Prevent Contamination
Cited by Susan M Jackson, Michele Perry Williams
9 Apr 2009
21 CFR 211.113(b)
Procedures for sterile drug products
Cited by Susan M Jackson, Michele Perry Williams
9 Apr 2009
21 CFR 211.186(b)(9)
Complete instructions, procedures, specifications et. al.
Cited by Susan M Jackson, Michele Perry Williams
Inspected site
APAurobindo Pharma LimitedMedchal, India
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.113(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.165(e) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.186(b)(9) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.42(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.80(b) | Cited across public-safe Form 483 observations | 1x |
Full 483 report
Get the verbatim text of all 5 observations
Every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere